Effects of NSAIDs on Colorectal Cancer Cells
Author Information
Author(s): Gardner S H, Hawcroft G, Hull M A
Primary Institution: University of Leeds
Hypothesis
Do different nonsteroidal anti-inflammatory drugs (NSAIDs) affect β-catenin levels and related transcription in human colorectal cancer cells?
Conclusion
The study found that most NSAIDs tested reduced β-catenin protein levels and cyclin D1 expression in colorectal cancer cells, except for the selective COX-2 inhibitor rofecoxib.
Supporting Evidence
- Indomethacin treatment reduced β-catenin protein levels significantly.
- Diclofenac showed a concentration-dependent antiproliferative effect.
- Sulindac metabolites demonstrated potent antiproliferative activity.
- Rofecoxib had little effect on cell proliferation compared to other NSAIDs.
- All NSAIDs except rofecoxib reduced cyclin D1 protein levels.
Takeaway
This study looked at how certain pain relievers called NSAIDs can change the levels of a protein linked to cancer in cells from the colon. Most of them helped lower the protein levels, which might help in fighting cancer.
Methodology
The study involved treating SW480 human colorectal cancer cells with various NSAIDs and measuring changes in β-catenin protein levels, cyclin D1 protein levels, and catenin-related transcription.
Potential Biases
Potential bias due to the use of a single cell line and the concentration ranges of NSAIDs tested.
Limitations
The study used only one cell line, which may not represent all colorectal cancer types.
Participant Demographics
SW480 human colorectal cancer cells, which do not express COX-2.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website